Company
Every investor coverage indicates participated in a round Snoretox raised.
Companies Snoretox acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Snoretox. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of Snoretox, a biotech using a modified tetanus toxin to strengthen weak muscles in dogs and humans, which has won a $1 million government research grant and is seeking investors.
Wholesale Investor's Steve Torso highlights Australian life sciences companies from the Emergence Preview Series, noting government grant funding, a Series A extension, venture co-investment, and a medtech company's ASX listing.
Also Wholesale Investor
Snoretox, a RMIT University spin-off developing modified tetanus toxin drugs, announced it raised more than one million dollars to commercialise ToneTox and SnoreTox.